急性冠症候群の世界市場-2022-2029年

市場力学

世界の急性冠症候群市場の成長は、急性冠症候群患者の急増、慢性疾患の有病率の上昇、高血圧、高血圧症、肥満の症例数の増加など、多くの要因によって牽引されています。

世界の慢性疾患の有病率上昇と技術的進歩の高まりが市場成長を牽引しています。

世界的に不健康なライフスタイルや環境の変化により、心不全、心血管疾患、冠動脈疾患などの慢性疾患の有病率が上昇していることが、市場の牽引役となっています。全米健康・栄養調査（NHANES）のデータ（2020年）によると、推定620万人の20歳以上のアメリカ人成人（2.2%）が心不全を患っています。570万人以上のアメリカ人が心不全を患っており、年間約915,000人の新規患者が診断されています。心不全が進行した患者様には、補助人工心臓が血液を体内に送り込み、弱った心臓をサポートします。

米国心臓協会の報告書2022年によると、社会経済的に貧しい診療所で治療を受けた冠動脈疾患のメディケア患者（サービス料）は、不安定狭心症で入院するリスクが高いことが判明しました。したがって、これらの冠動脈疾患は増加しており、急性冠動脈市場の成長につながっています。

急性冠症候群の治療における技術的進歩の増加も、世界的に心臓補助装置の成長を促進しています。例えば、2021年6月、アボット社は、高度な心不全を適切に治療するための機械的循環支援装置の需要増をサポートできると発表しました。

急性冠症候群の治療に伴う高コストが、市場の成長を阻害します。

しかし、アジアなどの価格に敏感な地域では、急性冠症候群治療薬の高額な費用が市場に影響を与える可能性があります。これらの地域では、患者や医師はより安価な治療法や手術法を好みます。急性冠症候群の治療薬は高価です。これは、急性冠症候群市場の成長に対する世界の主要課題の1つです。

COVID-19の影響分析

パンデミックは、サプライチェーンの混乱も引き起こし、医療製品の世界市場に影響を及ぼしています。パンデミックは、世界の金融への期待、サプライチェーン、オペレーション、危機対応戦略などに悪影響を及ぼしています。COVID-19の蔓延による閉鎖や渡航制限のため、新規の急性冠症候群治療薬のメーカーが問題に直面しました。COVID-19感染の拡大は主要な経済に大きな影響を与えたため、急性冠症候群治療薬の生産は大きな影響を受けた。

市場参加者は、研究市場を活用し、パンデミックに対抗する最先端のアイテムを作成することで、長期的および短期的な成長戦略を変えています。COVID-19が急性冠症候群産業に害を与えても、事業運営のためにできるだけ早くバックアッププランを準備し、実行することが重要です。

世界の急性冠症候群市場レポートでは、約40以上の市場データ表、45以上の図、200ページ（概算）にアクセスできると思われます。

目次

第1章 市場調査手法とスコープ

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 慢性疾患の増加
    • 老年人口の増加
  • 抑制要因
    • 治療用手術のコスト高
    • 心臓血管系デバイスに関連する高い価格
    • 厳しい規制
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 タイプ別

• ST上昇型心筋梗塞
• 非ST上昇型心筋梗塞
• 不安定狭心症

第8章 薬剤別

• 抗血栓薬
• 降圧剤
• スタチン系薬剤

第9章 エンドユーザー別

• 病院
• 専門クリニック
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク

第12章 企業プロファイル

• Teva Pharmaceuticals
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Dr. Reddy's Laboratories
• Boehringer Ingelheim
• Johnson & Johnson
• Merck
• Novartis
• Amgen Inc.
• AbbVie Inc.
• AstraZeneca PLC
• GlaxoSmithKline Plc

第13章 急性冠症候群の世界市場-DataM

Market Overview

Acute Coronary Syndrome Market was valued at US$ 28,992.31 million in 2021 and is estimated to reach US$ 78,626.54 million by 2029, growing at a CAGR of 8.74% during the forecast period (2022-2029).

Acute coronary syndrome (ASC) occurs when a blood clot suddenly forms within a coronary artery, usually due to the acute rupture of an atherosclerotic plaque. The blood clot may produce partial or complete blockage of the artery, placing the heart muscle supplied by that artery in immediate jeopardy.

Market Dynamics

The global acute coronary syndrome market growth is driven by many factors, such as the rapid surge in acute coronary syndrome cases, the rising prevalence of chronic diseases and increasing cases of high blood pressure, hypertension and obesity.

The increasing prevalence of the chronic disease across the globe and rising technological advancements are driving the market growth.

The market is driven by the rising prevalence of chronic ailments like heart failure, cardiovascular disease, and coronary artery disease due to unhealthy lifestyles and changing environments worldwide. According to the National Health and Nutrition Examination Survey (NHANES) data (2020), an estimated 6.2 million American adults ≥20 years of age (2.2%) had heart failure. More than 5.7 million Americans suffer from heart failure, and approximately 915,000 new patients are diagnosed annually. For patients with advanced heart failure, ventricular assist devices support the weakened heart by pumping blood through the body.

According to the American Heart Association report 2022, Medicare patients (service fee) with coronary artery disease who received treatment at socioeconomically impoverished practices were at higher risk of being admitted for unstable angina. Hence these coronary artery diseases are increasing, leading to the growth of the acute coronary market.

Increasing technological advancements in acute coronary syndrome treatment are also fuelling the growth of cardiac assist devices globally. For instance, in Jun 2021, Abbott announced that the company could support the growing demand for mechanical circulatory support devices to treat advanced heart failure properly.

The high cost associated with acute coronary syndrome treatment will hamper the market's growth.

However, in price-sensitive regions such as Asia, the high cost of acute coronary syndrome therapeutics may impact the market. In these areas, patients and doctors prefer less expensive therapies or surgeries. Acute coronary syndrome treatments are expensive. This is one of the major global challenges to the acute coronary syndrome market's growth.

COVID-19 Impact Analysis

The pandemic has also caused supply chain disruptions, impacting the world market for medical products. The pandemic has negatively impacted global financial expectations, supply chains, operations, and crisis response strategies. Due to lockdowns and travel restrictions brought on by the spread of COVID-19, makers of novel acute coronary syndromes treatment experienced problems. Because the spread of COVID-19 infections badly impacted major economies, acute coronary syndrome therapeutics production was greatly impacted.

Market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Even though COVID-19 harms the acute coronary syndrome industry, preparing and implementing backup plans as soon as possible for business operations is crucial.

Segment Analysis

The ST-elevation myocardial infarction segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

ST-elevation myocardial infarction shows significant growth, accounting for the largest market share, due to the regulatory approval for ST-elevation myocardial infarction drugs. For instance, in Jun 2020, AstraZeneca announced that Brilinta (ticagrelor) received approval from US Food and Drug Administration. Brilinta is used for reducing first stroke or heart attack risk in patients at high risk with coronary artery disease.

New technological advancements, novel pipelines, and clinical research in acute coronary syndrome treatments will also lead to market growth. For instance, in Aug 2022, AstraZeneca presented its novel results from the analysis of phase III trials of DAPA-HF and DELIVER that shows the mortality benefit of Farxiga over placebo in heart failure patients.

Geographical Analysis

The North American region holds the largest global acute coronary syndrome market.

North America dominates the acute coronary syndrome market and is expected to show a similar trend over the forecast period. The growth of North American acute coronary syndrome can be attributed to the rising prevalence of heart failure cases and the surge in the geriatric population. Strong healthcare infrastructure and an increase in research and development expenditure are to blame for this supremacy.

Furthermore, the rising prevalence of chronic diseases like myocardial infarction, unstable angina, etc., in this region due to unhealthy lifestyles and diets has propelled acute coronary syndrome treatment demand in the market. According to the American Heart Association report 2020, approximately 790,000 people in the U.S. have heart attacks yearly. The rising number of people suffering from cardiovascular diseases and growing technological advancements and mergers or acquisitions by key players boost the demand for acute coronary syndrome treatment in this region. For instance, in Jun 2021, Abiomed announced its acquisition of a precardiac catheter developer that provides less invasive options for treating patients with acute decompensated heart failure.

Competitive Landscape

The acute coronary syndrome market is highly competitive with local and global companies. Some key players contributing to the market's growth are Teva Pharmaceuticals, Dr. Reddy's Laboratories, Boehringer Ingelheim, Johnson & Johnson, Merck, Novartis, Amgen Inc., AbbVie Inc., AstraZeneca PLC and GlaxoSmithKline Plc among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the acute coronary syndrome market globally. For instance, in May 2022, Johnson and Johnson announced that its results from XARELTO (rivaroxaban), combined with the acetylsalicylic acid (XATOA) registry, were published in the European Heart Journal of the European Society of Cardiology. This study supports XARELTO's dual pathway inhibition role in coronary artery disease patients.

In Sep 2022, Abiomed announced that U.S. FDA approved two clinical research Impella heart pumps that can be used in acute myocardial infarction.

Teva Pharmaceuticals.

Overview:

Teva Pharmaceuticals is a multinational pharmaceutical company established in 1901 and headquartered in Tel Aviv, Israel. It specializes in generic drugs (primary), active pharmaceutical ingredients and proprietary pharmaceuticals.

Product Portfolio:

Ranexa: Ranolazine is a medicine used to treat chest pain related to the heart, such as chronic stable angina. It improves the blood flow toward the heart and makes it work efficiently. It can be used in combination with other medicines.

The global acute coronary syndrome market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of chronic diseases
    • 4.1.1.2. Growing geriatric population
  • 4.1.2. Restraints:
    • 4.1.2.1. The high cost of therapeutic surgeries
    • 4.1.2.2. High price associated with the cardiovascular devices
    • 4.1.2.3. Stringent regulations
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. ST-Elevation Myocardial Infarction*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Non-ST-Elevation Myocardial Infarction
• 7.4. Unstable Angina

8. By Drugs

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 8.1.2. Market Attractiveness Index, By Drugs
• 8.2. Antithrombotic*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Antihypertensive
• 8.4. Statin Drugs

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospital*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Specialty Clinics
• 9.4. Other

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Company Profiles

• 12.1. Teva Pharmaceuticals*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Dr. Reddy's Laboratories
• 12.3. Boehringer Ingelheim
• 12.4. Johnson & Johnson
• 12.5. Merck
• 12.6. Novartis
• 12.7. Amgen Inc.
• 12.8. AbbVie Inc.
• 12.9. AstraZeneca PLC
• 12.10. GlaxoSmithKline Plc

LIST NOT EXHAUSTIVE

13. Global Acute Coronary Syndrome Market - DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us